Vertex is asking FDA approval of elexacaftor (VX-445), tezacaftor, and ivacaftor (Kalydeco) to treat CF patients unable to benefit with current therapies. Read more about it here.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkRead more